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We applied our new method, maturity-dependent fractionation of bone marrow-derived neutrophil progenitors, to a
study of gene expression profiles during granulopoiesis in myelodysplastic syndromes. CD34+ cells with low density
[F1], CD11b-/CD16- [F2], CD11b+/CD16- [F3] and CD11b+/CD16low [F4] with intermediate density, CD11b+/CD16int [F5]
and CD11b+/CD16high [F6] with high density were isolated from six patients. Although AML1 and C/EBP-ε mRNA
peaked at F1 and F4, respectively, in healthy individuals, C/EBP-ε was maximized at F2/F3 in all patients, two of whom
showed simultaneous peaks of AML1 at F2. Thus, this fractionation is useful to detect mistimed induction of
granulopoiesis-regulating genes in myelodysplastic syndromes.
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Myelodysplastic syndromes (MDS) are clonal disorders
of hematopoietic stem cells characterized by cytopenia
with dysplastic phenotypes of myeloid cells [1], which
have been thought to result from defective differenti-
ation [2]. However, the molecular basis of impaired
differentiation is largely unclear. Since in vivo gene ex-
pression profiles during granulopoiesis in MDS have not
been studied because of the lack of an appropriate
method to fractionate progenitors, we applied our newly
established method that separates bone marrow (BM)-
derived neutrophil progenitors into six sequential matur-
ation stages [3] for BM specimens of six low-risk MDS
patients (Table 1). All volunteers provided a written form
of informed consent in accordance with the institutional
Human Research Committee and Helsinki Declaration.
Heparinized BM blood was divided into low (<1.065 g/mL),
intermediate (between 1.065 g/mL and 1.080 g/mL),
and high density (>1.080 g/mL) populations. The* Correspondence: yayois@fmu.ac.jp
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stated.overall recovery rate (73.7 ± 12.4%) did not differ from
the results of healthy BM [3]. Non-neutrophil lineages
expressing CD2, CD3, CD14, CD19, CD56, CD61,
glycophorin-A, or CD49d were eliminated, and the
remaining cells were subjected to immunostaining for
fluorescence activated cell sorting of CD34+ cells with low
density [F1], CD11b-/CD16- [F2], CD11b+/CD16- [F3],
and CD11b+/CD16low [F4] with intermediate density, as
well as CD11b+/CD16int [F5] and CD11b+/CD16high [F6]
with high density. The six fractions derived from MDS pa-
tients well correlated with morphological maturation of
neutrophil progenitors (Table 2), as previously shown
using healthy BM.
The BM-derived fractions and a peripheral blood-
derived neutrophil fraction [F7] were subjected to quanti-
fication of mRNA of acute myeloid leukemia 1 (AML1),
CCAAT-enhancer-binding protein-epsilon (C/EBP-ε), and
ecotropic viral integration site 1 (EVI1) as previously de-
scribed [3]. As shown in Figure 1, four out of the six pa-
tients showed peak expressions of AML1 mRNA at F1
followed by a gradual decrease as previously shown in
healthy BM [3]. However, two patients, refractory cytope-
nia with multilineage dysplasia (RCMD)1 and RCMD2,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Table 1 Clinical and hematological findings and treatment in six patients with MDS
Diagnosis Age/sex WBC (×109/L) ANC (×109/L) Hb (g/dL) PLT (×109/L) BM NCC (×109/L) Karyotypes Therapy
RCUD 74/M 4.5 3.5 8.4 206 143 46,XY None
RCMD 1 66/M 2.4 1.7 9.2 46 37 46,XY None
RCMD 2 79/F 3.5 2.0 10.3 6 50 46,XX RBC and platelet transfusion
RCMD 3 73/M 2.8 1.4 10.3 79 207 46,XY,del(20)(q11) None
RCMD 4 26/F 4.0 0.9 11.2 50 35 46,XX None
RARS 83/M 4.8 3.4 6.1 336 240 46,XY None
Abbreviations; WBC white blood cell counts, ANC absolute neutrophil counts, Hb concentration of hemoglobin, PLT platelet counts.
BM NCC bone marrow nucleated cell counts, M male, F female, RBC red blood cells, RCUD refractory cytopenia with unilineage dysplasia, RCMD refractory
cytopenia with multilineage dysplasia, RARS refractory anemia with ringed sideroblasts.
Table 2 Morphological counts of the cells included in sorted fractions
MB PM MC MM SB SE Others
F1 69.7 ± 23.7% 29.3 ± 22.8% 0.3 ± 0.3% 0.0 ± 0.0% 0.0 ± 0.0% 0.0 ± 0.0% 0.7 ± 0.6%
F2 0.0 ± 0.0% 47.8 ± 16.1% 55.8 ± 17.1% 0.5 ± 0.4% 0.3 ± 0.4% 0.0 ± 0.0% 2.5 ± 4.8%
F3 0.2 ± 0.4% 0.5 ±0.5% 80.1 ± 18.0% 11.4 ± 14.7% 1.3 ± 1.9% 0.2 ± 0.5% 5.7 ± 11.4%
F4 0.0 ± 0.0% 0.3 ± 0.8% 70.3 ± 29.0% 24.6 ± 20.6% 4.3 ±5.9% 0.4 ± 0.7% 0.0 ± 0.0%
F5 0.0 ± 0.0% 0.0 ± 0.0% 17.4 ± 8.3% 29.8 ± 20.1% 49.4 ± 24.3% 7.9 ± 7.2% 1.3 ± 3.0%
F6 0.0 ± 0.0% 0.0 ± 0.0% 1.1 ± 1.5% 7.0 ± 4.9% 57.5 ± 11.5% 34.4 ± 15.7% 0.1 ± 0.2%
The numbers represent mean ± SD. MB; myeloblasts, PM; promyelocytes, MC; myelocytes, MM; metamyelocytes, SB; neutrophils with stab nuclei, SE; neutrophils
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Figure 1 Expression profiles of AML1, C/EBP-ε, and EVI1 mRNA in each MDS patient. The ratio of AML1, C/EBP-ε, or EVI1 to β-actin mRNA
in F1 was plotted as 1.0 in each panel. NE; not examined, ND; not detected.
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28- and 1.8-fold higher than those at F1, respectively. The
delayed peak of AML1 mRNA was not due to the contam-
ination of myeloblasts (MBs) in F2, since RCMD1- and
RCMD2-derived F2 consisted of mostly promyelocytes
(PMs) and myelocytes (MCs), with no MBs. The peak ex-
pression of C/EBP-ε mRNA was detected at F2 in four pa-
tients and at F3 in one patient, while the other patient
showed two peaks at F2 and F4. In healthy BM, C/EBP-ε
mRNA was maximally expressed at F4 [3] following the ac-
quisition of cell-surface expression of CD11b. Simultaneous
peaks of C/EBP-ε and AML1 at F2 in RCMD1 and RCMD2
were obviously abnormal. The remarkable dropdown and
absence of EVI1 mRNA at F2 of RCMD1 and RCMD2,
respectively, suggested that both AML1 and C/EBP-ε
mRNA were specifically increased at F2 in these patients.
These aberrant gene inductions were not detectable by
analyses of only a hematopoietic stem cell fraction [4,5],
or density-based three fractions [6] which includes F2,
F3, and F4 in the same fraction with intermediate dens-
ity. Thus, our newly established method of neutrophil
progenitor fractionation is applicable to MDS, and may
provide a new insight into understanding the molecular
basis of impaired differentiation.
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